Cell Therapeutics - ein Kursvervielfacher? - 500 Beiträge pro Seite

[Macrocosmonaut [Blogger]]

Die Aktie von Cell Therapeutics (NASDAQ-Kürzel: CTIC) kam im letzten Jahr arg unter die Räder und musste einen herben Kursrückgang für engagierte Investoren hinnehmen.

Das schlimmste scheint aber nunmehr überstanden, so dass en Blick auf die Charttechnik lohnenswert erscheint.

Hier bahnt sich bereits ein kräftiger Rebound auf der Longseite in den kommenden Wochen und Monaten an.

Im Wochenchart zeichnet sich ein concealling swallow baby als Trendumkehrmuster mit hoher Aussagekraft ab.

Die MACD hat auf MOnatsbais - so wie schon lange die AMCD auf Wochenbasis - auf kaufen gedreht.

Beeindruckend ist die Entwicklung und weitere deutliche Zunahme der positiven Divergenzen in den letzten Monatenbei diesem Wert.

Markttechnische habe die Ozillatoren auf kaufen gedreht.

Die Bollinger Banden haben ebenso angefangen nach oben zu drehen.

William R% kündigt einen kräftigen Counterimpuls zur Oberseite an.

Aus technischer Sicht erscheint das Chance/Risikoprofil auf der Longseite daher derzeit äusserst attraktiv, wobei in den kommenden Wochen auch hier mit einer Kaskadierung der Kaufsignal gerechnet werden muss.

Ein Überschreiten der Widerstandslevel bei 3.50 US$ sollte inder Folge einen raschen Kursanstieg bis 5.60 US$ nach sich ziehen.

Fällt auch diese Marke, dann steht langfristig auch höheren Kursen im zweistelligen US$-Bereich nichts im Wege.

Diese werden dann zum gegebenen Zeitpunkt diskutiert.

Die Fundamentals wurden in anderen Threads ja schonausgiebig dargestellt. Im Mai ist die ASCO so dass, auch hier neue Interimsergebnisse erwaret werden können.

Wie immer meine eigene Einschätzung und ohne Gewähr.

Macrocosmonaut.

[RTLOLDY]

[posting]20.651.661 von Macrocosmonaut am 12.03.06 17:57:15[/posting]Kannst du es anhand dieser Grafiken nochmals genauer erklären????







Gruss
OLDY

[mindgames1001]

Die Aktie hat einen aggressiven,intakten Downtrend.Da nützt auch das ganze Geschwätz nichts.

Diesen gilt es erstmal zu brechen!

[mindgames1001]

Und zudem wenn Sie von Kursen um 5.60 Dollar sprechen dann würde Ich auch sagen dass es min. 2 Jahre dauern kann und Kurs 1 Euro noch realer scheint.

[mindgames1001]

Der Hammer:

empfiehlt am 09.01. STRONG SELL bei Solarworld,also bevor Sie von 100 auf 238 Euro steigt.



Und dann ein paar Cell Aktien holen und empfehlen,trotz negativen Trend und nix in der Pipeline.

[wachholder]

Ich habe mir die Firma sehr gut angeschaut.
Ich glaube nicht, dass Cell Therapeutics nochmal die Kurve bekommt. Der Chart sagt alles.
XYOTAX wird erneut durchfallen und ansonsten hat CTIC nicht viel in der Pipeline.

Da ich aber unbedingt in ein aufstrebendes unterbewertes Biotech Unternehmen investieren wollte, habe ich mich für Titan Pharmaceuticals entschieden.
Schaut Euch mal den Hauptthread an, da steht alles drin.

wachholder

[RTLOLDY]

[posting]20.651.932 von mindgames1001 am 12.03.06 18:18:11[/posting]Meine Meinung:

Der Primärtrend läuft eindeutig nach unten,
da nützen auch alle positiven Sekundärtrends nichts.

Da muss schon eine Hammer-News kommen,
damit sich daran etwas ändert!

OLDY

[mindgames1001]

@rtl,wacholder:

denke Ich auch,die Aktie hat längerfristig KZ 0 oder 1 Euro

[mindgames1001]

@wacholder:

TITAN sieht super aus!



3 Monate AMEX

[RTLOLDY]

............. und ich steige bei so einem Trend ein.



PS:
Name nenne ich nicht, da ich schon mal wegen "SPAM" gesperrt war!!!!

OLDY

[RTLOLDY]

[posting]20.652.082 von mindgames1001 am 12.03.06 18:31:47[/posting]Gib mir mal das Symbol von (deinem) Titan !!!

Danke
OLDY

[RTLOLDY]

[posting]20.652.082 von mindgames1001 am 12.03.06 18:31:47[/posting]Hmmmmmmmmmm..............

[mindgames1001]

was sind das allg. für Charts????

[RTLOLDY]

[posting]20.652.301 von RTLOLDY am 12.03.06 18:51:58[/posting]Schau mal auf dein Posting....
20.652.082 von mindgames1001 am 12.03.06 18:31:47

Rest über BM

OLDY

[RTLOLDY]

[posting]20.652.355 von RTLOLDY am 12.03.06 18:58:50[/posting]mindgames1001,
du hast BM

[wachholder]

RTLOLDY

Kürzel TTP
WKN 914404

Hier zwei Links hinsichtlich der Pipeline von Titan.
http://www.titanpharm.com/overview.html
http://www.titanpharm.com/studies.html

Und das Ganze bekommt man für ca. 125 Mio Marktkapitalisierung......noch!!

wachholder

[silesian]

PALO ALTO, Calif., March 10 /PRNewswire-FirstCall/ -- CV Therapeutics, (Nachrichten) Inc. announced today that the company has begun filling orders and shipping Ranexa(TM) (ranolazine extended-release tablets) to pharmaceutical wholesalers.
CV Therapeutics anticipates that Ranexa will be available in pharmacies by late March, when the company`s cardiovascular sales force expects to begin calling on cardiology specialists.
On January 27, 2006, the U.S. Food and Drug Administration approved Ranexa for marketing in the United States. The approval of Ranexa marks the first new pharmaceutical approach to treat angina in more than 20 years in the United States. Ranexa has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure.
According to the approved product labeling, Ranexa is indicated for the treatment of chronic angina. Because Ranexa prolongs the QT interval, it should be reserved for patients who have not achieved an adequate response with other antianginal drugs. Ranexa should be used in combination with amlodipine, beta-blockers or nitrates. The effect on angina rate or exercise tolerance appeared to be smaller in women than men. Complete prescribing information for Ranexa, including detailed safety and dosage information, is available at http://www.ranexa.com/.

[Marchella]

Das amerikanische Biopharma-Unternehmen Cell Therapeutics Inc. (CTI) (ISIN US1509341079/ WKN 906780) verbuchte im vierten Quartal 2005 einen herben Rückgang bei Umsatz, konnte aber den Verlust reduzieren.

Unternehmensangaben vom Dienstag zufolge sanken die Umsatzerlöse auf 1,2 Mio. Dollar, verglichen mit 8,1 Mio. Dollar im Vorjahresquartal.

Der Nettoverlust verringerte sich derweil von 43,5 Mio. Dollar oder 72 Cents je Aktie auf nun 18,7 Mio. Dollar bzw. 27 Cents pro Aktie.

Analysten hatten im Vorfeld einen Verlust von 16 Cents je Aktie und einen Erlös von 110 Mio. Dollar erwartet.

Die Aktie notierte zuletzt bei 1,93 Dollar.

Wertpapiere des Artikels:
CELL THERAPEUTICS, INC.


Autor: SmartHouseMedia (© wallstreet:online AG / SmartHouse Media GmbH),21:18 09.03.2006

[Macrocosmonaut [Blogger]]

[posting]20.651.877 von RTLOLDY am 12.03.06 18:13:08[/posting]1. Ihre MACD hat erstens kein Verkaufssignal generiert - sie kreisen in ihrem Chart nur eine Erwartung ein.

2. Auf Wochenbasis liegt bereits seit rund drei MOnaten ein Kaufsignal in der AMCD vor.

3. DAs Momentum entwicklet sich nach oben und nicht nach unten - ablesbar an den positiven Divergenzen.

4. Die Kerzenkörper der letzten MOnate im Tageschart sind klein und im Makrochart allesamt faktisch gar nicht vorhanden - von einer Abwärtsdynaik ist weit und breit nichts mehr zu erkennen.

5. Das Sentiment ist extrem negativ - ein weitere Hinweis für eine anstehende stärkere Aufwärtsbewegung.

6. Weitere Kufsignale liegen vor gepaart mit einem Volumensignal, dass ein klarer Hinweis ist auf das Ende der laufenden Abwärtsbewegung.

Ich werde solche Werte auf diesem Niveau nicht shorten - wer dies tun will soll es machen sich aber nicht wundern, wenn er hinterher sich die Finger verbrennt.

Wie immer meine eigene Einschätzung und ohne Gewähr.

Macrocosmonaut.

P.S.: Vorsicht bei Titan - der Wert ist bereits sehr gut gelaufen - der letzte macht dort das Licht aus. Zu Solarworld noch ein Wort.

Der Wert ist mittlerweile die am größten aufgeblähte Frittenbude am deutschen Markt, die ich kenne.

Aran hat sich nichts geändert - der Wert ist gnadenlos überbwertet und das war er bereits vor 2 Jahren.

Soclhe Werte lass ich links liegen und die schaue ich mir vielleicht an wenn sie 90% an Wert verloren haben - freilich der Markt handelt irrational - wer aber glaubt mit SOlarworld nochmals 100% oder mehr Gewinn zu machen der sollte sich vor Augen führen das der Wert dazu auf über 400 Euro steigen muss und um sich zu derdreifachen sogar auf 700 Euro. Wer an solche Utopien glaubt bitte schön...

Wie gesagt es gibt eine Vielzahl besserer Werte an den Aktienmärkte dieser Welt als eine Solarworld oder eine der anderen Frittenbuden aus dem Solarsektor.

Im übrigen wurde die Shortposition bei Solarworld damals ausgestoppt -was ich auch gepostet hatte.

Aber wie immer ist dies meine eigene Einschätzung und ohne Gewähr.

Macrocosmonaut.

[Augenzu]

Bewegung an der Vorbörse

[Macrocosmonaut [Blogger]]

[posting]20.652.023 von RTLOLDY am 12.03.06 18:26:38[/posting]Der Primärtrend wurde heute mit einem breakaway gap überwunden und somit neutralisiert.

Desweiteren liegen weitere Kaufsignale bei dem Wert vor:

EMA(kurz) wurde positiverweise ebenfalls überschritten.

MACD Kaufsignal auf Tages- und Wochenbasis.

Ansteigendes Momentum.

Bullisches Kerzenmuster.

Positive Divergenzen, die förmlich nach einer Auflösung nach oben "schreien".

Dazu Kaufsignale von Frühindilatoren auf Wochenbasis und Tagesbasis mit entsprechendem Vorlaufcharakter.

Spätestens mit dem heute erfolgten Bruch des primären Abwärtstrendes (auch im log view) sollten shortpositionen geschlossen werden - zumal der Wert in den letzten 2 Wochen eine Reihe von Kaufsignalen generiert hat..

Wie immer meine eigene Einschätzung und ohne Gewähr.

macrocosmonaut.

[loseit]

Hallo kosmonaut,

kenne Dich noch aus finanzen.net und habe dort Deine Beiträge stets zu schätzen gewusst. - Schön Dich hier wiederzusehen.

Bin mit einer Einstiegsposition bereits drin. Sehe deutliches Potenzial; gefühlsmässig scheint mir z.Zt. eher das Scheitern eingepreist; d.h. bei positiven News geht`s up!

Gruss Loseit

[Macrocosmonaut [Blogger]]

Antwort auf Beitrag Nr.: 20.651.661 von Macrocosmonaut am 12.03.06 17:57:15

Kurzupdate - wegen Zeitmangels (AAD-Meeting in Düsseldorf)

Charttechnisch nunmehr weitere neue Kaufsignale - auch im strategischen Sinne.

Erstes Kursziel auf mittlere Sicht in den kommenden Wochen liegt bei 3.52 US$ (vorgelagert 2.48 US$).

MACD weekly mit Kaufsignal (weist auf einen mittel und langfristig aufwärtsgerichtete Kursentwicklung hin)

Wie immer meine eigene Einschätzung und ohne Gewähr.

Sofern ich es zeitlich schaffe werde ich eine ausführlilche Analyse demnächst einstellen.

Happy days.

Macro.

[Macrocosmonaut [Blogger]]

Antwort auf Beitrag Nr.: 20.913.858 von loseit am 22.03.06 19:56:26

Sorry, ich habe mit Finanzennet nichts zu tun. Da muss eine Verwechselung vorliegen.

Schönen Gruß.

M.

[danielcomm]

kaufen

[Macrocosmonaut [Blogger]]

Antwort auf Beitrag Nr.: 20.927.697 von Macrocosmonaut am 23.03.06 20:51:02

Offenbar werden auch andere nun auf den Wert aufmerksam:

http://www.deraktionaer.de/xist4c/web/Das-Comeback-des-Jahre…

MfG.

Macrocosmonaut.

[Macrocosmonaut [Blogger]]

Antwort auf Beitrag Nr.: 20.927.697 von Macrocosmonaut am 23.03.06 20:51:02

Tages- und Wochenschluss oberhalb der 38 und 50 GD - dazu Bruch des Abwärtstrendes auf Wochenschlusskursbasis.

Das Chartbild hat sich zum Wochenschluss - auch in Form eines bullisch harami cross deutlich verbessert.

Dazu passt auch das Umfeld in den Trendfolgeindikatoren und das weiter steigende Momentum.

Wie immer meine eigene Einschätzung und ohne Gewähr.

Macrocosmonaut.

[sukashi]

Antwort auf Beitrag Nr.: 20.958.364 von Macrocosmonaut am 27.03.06 13:34:17

Danke Macrocosmonaut
Hier der genannte Bericht:

Cell Therapeutics war klinisch tot.
Jetzt kündigt sich die Wiederbelebung an. Anleger, die bis heute auf hohen Verlusten sitzen, dürfte es freuen.

Es hätte alles so schön sein können: Von August 2004 bis März 2005 bildete die Aktie des US-Biotech-Unternehmens Cell Therapeutics (CTIC) einen mustergültigen Aufwärtstrend aus. Das Papier legte von rund vier auf über elf Dollar zu. In der Erwartung der Zulassung des von CTIC Krebsmittels Xyotax griffen die Anleger beherzt zu. Dann der Schock: Die US-Gesundheitsbehörde FDA verweigerte CTIC aufgrund von Sicherheitsbedenken die Erlaubnis zur Vermarktung. Die Aktie fiel wie ein Stein. Bis heute hat sich das Papier nicht von diesem Rückschlag erholt, es dümpelt im Bereich von zwei Dollar vor sich hin. Doch dies könnte sich bald ändern. CTIC hat 2005 nicht nur sein Management ausgetauscht und rund 130 Arbeitsplätze abgebaut, sondern ist auch bei der Entwicklung seines wichtigsten Produktkandidaten entscheidend vorangekommen.

Krebsmittel vor Zulassung
Wie Insider heute berichten, hat sich die FDA die Entscheidung zu Xyotax im März letzten Jahres nicht leicht gemacht. Der Entschluss fiel nur sehr knapp zu Ungunsten des Mittels aus, das gegen Lungenkrebs eingesetzt werden soll. Das Unternehmen hat nach Absprache mit den Behörden inzwischen weitere Tests durchgeführt und diese bereits eingereicht. Und diese haben die FDA offensichtlich überzeugt. Denn nicht anders ist zu erklären, dass sie für die Indikation nicht-kleinzelliger Lungenkrebs bei Frauen den so genannten Fast-Track-Status erteilte. Dieser sichert dem Unternehmen ein beschleunigtes Zulassungsverfahren zu. Branchenexperten gehen davon aus, dass Xyotax noch 2006 die Zulassung für die EU bekommen wird und dass spätestens im kommenden Jahr die Vermarktungserlaubnis für die USA folgen wird. Das Marktpotenzial taxieren die Analysten auf mindestens 250 Millionen Dollar pro Jahr.

Fazit
Die Aktie von Cell Therapeutics ist und bleibt ein hochspekulatives Investment. Doch vor dem Hintergrund ei- ner möglichen Zulassung von Xyotax in Europa und später in den USA ist für die arg gebeutelten Aktionäre zumindest Licht am Ende des Tunnels in Sicht. Sollte CTIC die Erlaubnis zur Vermarktung erhalten, hat die Aktie Verdopplungspotenzial. Die Position sollte durch einen engen Stopp im Bereich von 1,50 Euro abgesichert werden.
Hier ist wirklich in nächster Zeit alles oder nichts zu erwarten-
bei positiven News erwartet uns ein Feuerwerk an Steigerung,
bei negativen News ab weiter nach Süden.

Traue mir persönlich keine definitive Variante zu.

Warten wirs in Ruhe ab-
Sukashi

[DMKE]

was ist denn hier heute los ?

[loseit]

Antwort auf Beitrag Nr.: 21.115.101 von DMKE am 07.04.06 09:49:33

Cell Therapeutics, Inc. (CTI) Announces Intention to Sell or Exchange a New Series of Convertible Notes
Thursday April 6, 7:00 am ET

SEATTLE, April 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) announced today its intention to sell or exchange, subject to market and other conditions, between $50,000,000 and $100,000,000 principal amount of a new series of convertible notes to qualified institutional buyers or holders of its existing notes in a transaction exempt from the registration requirements of the Securities Act of 1933, as amended. The terms of the notes and any exchange of those notes for existing notes will be determined through negotiations with potential buyers and existing noteholders

[DMKE]

Antwort auf Beitrag Nr.: 21.115.490 von loseit am 07.04.06 10:07:30

ähm, und was heisst das jetzt ... mein englisch reicht dafür nicht ganz sorry ...

[loseit]

Antwort auf Beitrag Nr.: 21.116.653 von DMKE am 07.04.06 11:06:00

Ohne Englisch würde ich keine US-Aktien kaufen...

Kurz gesagt: Kapitalerhöhung.

Gruss Loseit

[Macrocosmonaut [Blogger]]

Antwort auf Beitrag Nr.: 21.119.072 von loseit am 07.04.06 13:33:11

Der Chart hat sich gestern erheblich eingetrübt - allerdings trägt die gestrige Kursbewegung Züge eines sell offs.

Am montasende könnte durchaus das ganze als lange Lunte imponieren - auch mit Blick auf das Volumensignal.

Mal sehen, was aus dem ganzen wird.

Macrocosmonaut.

[pikbube]

Mal schauen was nach dieser Meldung passiert - Gruß pikbube



Cell Therapeutics, Inc. (CTI) Granted U.S. Patent for New Potent Antitubulin Agents With Anti-Cancer Activity



Preclinical Studies Demonstrate Antiproliferative Activity in Tumor Cell Lines
Resistant to Standard Chemotherapy
SEATTLE, April 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) announced today that the United States Patent and Trademark Office granted a patent for a new class of small molecule antitubulin agents with potent antiproliferative and tumor killing activity. CT-45099 is the first lead optimized agent from this class of compounds to advance into preclinical testing. The patent, owned by CTI's European subsidiary, Cell Therapeutics Europe S.r.l. (CTI-Europe), covers analogs of CT-45099 and will expire in April 2022. CT-45099 is protected by a U.S. and European patent already granted to CTI-Europe.

Unlike the marketed taxane-based cancer drugs, Taxol(R) (paclitaxel) and Taxotere(R) (docetaxel), or even investigational new drugs like epothilones, which kill cells by stabilizing microtubules and preventing their disassembly, this class of agents blocks tubulin assembly and destabilizes microtubules during cell mitosis. Therefore, this class of agents has anti-tumor activity distinct from these other drugs. In addition, this new class of antitubulin agents is not susceptible to multi-drug resistance, one of the most common mechanisms by which cancer cells develop resistance to standard chemotherapies. CT-45099 and its analogs inhibit in vitro the growth of colon, lung, gastric, and prostate cancer cell lines, including cancer cells resistant to paclitaxel or doxorubicin treatment.

"This patent, and the new class of agents covered within, highlights our ability to take a well known target in cancer drug development, like tubulin, and apply our medicinal chemistry expertise to develop a novel class of anti-cancer agents that may possess superior anti-tumor activity over commonly used tubulin-stabilizing chemotherapy drugs," noted Alberto Bernareggi, Ph.D., Managing Director of CTI-Europe.

[Macrocosmonaut [Blogger]]

Antwort auf Beitrag Nr.: 21.143.759 von pikbube am 10.04.06 14:20:56

Es handelt sich nur um eine präklinische Studie - aber der Wert reagiert vorbörslich mit einem satten Kursplus von 14 %.

Nicht untypsiche Kursbewegung für Biotechs.

Mal sehen wie die Woche endet.

MfG.

Macrocosmonaut.

[Mümmelpütz]

Antwort auf Beitrag Nr.: 20.652.622 von wachholder am 12.03.06 19:25:27

Nur mal so am Rande: Was macht eigentlich die Aktie von Titan?
Gibt es da schon Neuigkeiten?

Gruß
MP

[PutenPeter]

So das Gab dürfte geschlossen werden.






Die Zwei $ sollten nach Ostern wieder erreicht werden.

[DMKE]

Antwort auf Beitrag Nr.: 21.164.016 von PutenPeter am 11.04.06 18:17:05

sehe hier sogar noch kurse unter 1, 40 € ...

[PutenPeter]

Antwort auf Beitrag Nr.: 21.170.971 von DMKE am 12.04.06 10:12:33

da möchte ich dir nicht wiedersprechen

[PutenPeter]

Nun das Gab ist da und es könnte sich ein W ausbilden.

[loseit]

Antwort auf Beitrag Nr.: 21.175.741 von PutenPeter am 12.04.06 14:58:14

So sieht es jedenfalls für einen, der an Charttechnik glaubt, zur Zeit aus.

Ich frage mich nur, wieso der Kurs z.Z. derart massiv springt -
ist das gezielte Manipulation im Vorfeld grösserer Ereignisse?

Aus dem Yahoo-Board sind z.B. keine "echten" Gründe für diese Sprünge für mich zu ersehen.

Gruss Loseit

[PutenPeter]

Antwort auf Beitrag Nr.: 21.175.946 von loseit am 12.04.06 15:08:18

Tod gesagte leben manch mal länger.

schon sehr merk würdig alles.

[PutenPeter]

Antwort auf Beitrag Nr.: 20.651.661 von Macrocosmonaut am 12.03.06 17:57:15

Cell Therapeutics ( CTIC ) Hopp oder Top


Ich sag mal Top zu diesen Hochriskanten Invest

Im Mai ist die ASCO vor einem Jahr ist Cell mit XYOTAX durchfallen. Mal schauen was in diesemJahr passiert der Kurs spricht zwar nicht da für aber die Umsätze

[Hirnstone]

SEATTLE, June 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, (Nachrichten) Inc. (CTI) (Nasdaq: CTIC; MTAX) announced that at a recent meeting with the U.S. Food and Drug Administration (FDA), CTI and the FDA agreed on a new drug application (NDA) route for XYOTAX(TM) (paclitaxel poliglumex) for women with lung cancer. The FDA agreed to review an NDA submission based on interim results of the PIONEER trial with the results of the STELLAR 3 and 4 trials to support the filing. Based on this feedback, if the PIONEER trial meets its pre-specified interim endpoint, CTI plans to submit an NDA in the first half of 2007 and would request a priority (six month) review based on the fast track designation, instead of the standard (ten month) review as previously planned.

"We are happy with the outcome from our pre-NDA meeting with the FDA, which focused on how best to utilize the survival data observed among women in the STELLAR 3 and 4 trials and confirmatory data from our ongoing gender- specific PIONEER trial," stated James A. Bianco, M.D., President and CEO of CTI.

"By reviewing an NDA based on interim data from the PIONEER study, this approach could reduce the approval process for this novel therapeutic by more than 12 months over a filing based on full results of the PIONEER study."

"Lung cancer is a major unmet medical crisis for women and will kill 70,000 women this year. The biology of lung cancer is different in women and they appear to respond differently to treatment than men. We need to examine the potential for gender-specific therapy, not only in lung cancer but in a number of cancers that are known to express the estrogen receptor. Increasing knowledge of human biology is the ultimate promise of personalized medicine," Bianco added.

About the PIONEER clinical trial

The PIONEER clinical trial is targeting approximately 170 sites in the United States, Eastern Europe, and Latin America. CTI expects to enroll approximately 600 PS2 chemotherapy-naive women with advanced stage NSCLC. Each study arm of approximately 300 patients will be randomized to receive either XYOTAX (at a dose of 175mg/m(2) paclitaxel equivalents) or paclitaxel (at a dose of 175mg/m(2)) once every three weeks. The primary endpoint is superior overall survival with several secondary endpoints including disease control, response rate in patients with measurable disease, time to disease progression, and disease-related symptoms.

About XYOTAX

XYOTAX(TM) (paclitaxel poliglumex) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Based on preclinical studies, it appears that XYOTAX is preferentially trapped in the tumor blood vessels allowing significantly more of the dose of chemotherapy to localize in the tumor. Preclinical and clinical studies support that XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com/.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of XYOTAX(TM) include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with XYOTAX in particular including, without limitation, the potential failure of XYOTAX to prove safe and effective for treatment of lung and ovarian cancers, the potential failure of the PIONEER trial to accrue patients in a timely manner or meet the requirements of the interim analysis, the potential for the FDA to not accept or approve the NDA in a timely manner or at all, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling XYOTAX, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

[schappi64]

wer hat neuigkeiten zu dieser aktie bitte wenns geht in deutsch.

[Macrocosmonaut [Blogger]]

Antwort auf Beitrag Nr.: 21.973.466 von schappi64 am 06.06.06 20:06:37

Einfach den Chart anschauen - der verarbeitet alle news.

Aktie erscheint günstig und chancenreich, nach dem Abverkauf der letzten Monate. Schönes island reversal jüngst ausgebildet - mal sehen wie es weitergeht.

Wie immer meine eigene Einschätzung und ohne Gewähr.

Happy days.

M.

[schappi64]

Antwort auf Beitrag Nr.: 21.973.876 von Macrocosmonaut am 06.06.06 20:35:32

vielen dank für die antwort und analyse.schönen abend noch.

[liasis]

<< Back
CTI to File for XYOTAX(TM) Marketing Approval in Europe on Equivalent Effectiveness (Non-Inferiority) and Superior Safety Using Existing STELLAR Clinical Trial Data

Scientific Committee of European Medicines Agency (EMEA) Agrees in Principle
to Switch From Superiority to Non-Inferiority

SEATTLE, June 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) announced today that the EMEA's Scientific Advice Working Party (SAWP) agreed in principle that a switch from the superiority endpoints in the STELLAR trials to non-inferiority endpoints could be justified as a pathway to approval. Their decision was based on the five key elements in the EMEA Points to Consider and the data presented at a recent meeting.

In addition, a shift in the non-inferiority margin may also be justified if the safety profile of XYOTAX(TM) (paclitaxel poliglumex) is superior to comparators in terms of important (serious) side effects and/or quality of life or use of rescue medications. CTI plans to file a marketing authorization application (MAA) in Europe in the first half of 2007 for XYOTAX as a single agent for first-line treatment of non-small cell lung cancer (NSCLC) in PS2 (ECOG performance status 2) patients.

"We had a very productive meeting with the scientific advisors for the EMEA," noted Scott C. Stromatt, M.D., CTI's Executive Vice President of Clinical Development and Regulatory Affairs. "The SAWP encouraged us to focus on all the clinically relevant XYOTAX safety data in our application to justify these changes to the statistical analyses, as well as to address the sensitivity of our assay when demonstrating non-inferiority. They agreed in principle with our position that it is clinically important to determine whether a drug like XYOTAX is non-inferior if it provides a more favorable risk/benefit profile for patients. This is a positive outcome given their willingness to review our application based solely on existing STELLAR trial data."

Lung cancer remains the biggest cancer killer in Europe. The incidence of lung cancer in Europe is more than 13 percent of all cancers, and in 2000 resulted in nearly 350,000 deaths.

As announced earlier this month, CTI and the U.S. Food and Drug Administration agreed on a new drug application (NDA) route for XYOTAX for women with lung cancer in which the FDA agreed to review an NDA submission based on interim results of the PIONEER trial with the results of the STELLAR 3 and 4 trials to support the filing. If the PIONEER trial meets its pre- specified interim endpoint, CTI plans to submit an NDA in the first half of 2007.

"This is a very exciting outcome for CTI and more importantly for patients with lung cancer. We now have a clear route for potential approval in both the United States and Europe with both regulatory agencies willing to accept the STELLAR trial results as supportive or, in the case of the EMEA, as pivotal. This could have a significant positive impact on both the time and cost for bringing this drug to market," commented James A. Bianco, M.D., President and CEO of CTI.

About the STELLAR Trials

The STELLAR trials are among the largest randomized, phase III trials to date in either second-line non-small cell lung cancer (NSCLC) or first-line PS2 NSCLC patients. STELLAR 2 tested XYOTAX versus docetaxel for the potential second-line treatment of NSCLC patients. STELLAR 3 tested carboplatin in combination with either XYOTAX or paclitaxel for the potential first-line treatment of poor performance status (PS2) patients with NSCLC. STELLAR 4 tested XYOTAX versus either gemcitabine or vinorelbine for the potential first-line treatment of poor performance status (PS2) patients with NSCLC.

About XYOTAX

XYOTAX(TM) (paclitaxel poliglumex) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.

[schappi64]

hat irgend einer neue nachrichten oder weiss was neues uber cell....?

[addicted]

jo societe generale steigt ein mit viel geld ich glaub die machen das sicher nich aus naechstenliebe grundsätzlich mal zu biotechs wie ist da eure strategie 5 teile nach ausgiebigem research kaufen und dann buy & hold und hoffen das mindestens 3 ne rakete werden für infos waer ich dankbar und was habt ihr zur zeit noch an aussichstreichen biotechs was haltet ihr von neurocrine nach dem crash

[schappi64]

schau dir mal co-don517360 an sehr gute firma.bin davon sehr überzeugt.wei kniebeschwerden werden immer mehr.

[reinl100]

Hi addicted
wo steht das mit der Societe generale geschrieben, in welcher Größenordnung kaufen die sich bei Cell ein?

[addicted]

bei marketwatch auch auf finanznews sowie auf ihrer website 50 millionen ist die größenordnung ich werd langsam einsteigen genr arql und ctic sind meine favoriten eure?

[loseit]

Antwort auf Beitrag Nr.: 22.311.331 von addicted am 28.06.06 10:11:09

Die Chancen auf eine Zulassung von XYOTAX könnten mit der "Non-inferioty" tatsächlich gestiegen sein:

------------------------------------------------------

I'm Back in the long Side after Jason Kantors
comments.

W.R. Hambrecht's Kantor thinks Xyotax is approvable based on its non-inferiority to Taxol in survival rates.
"There were three possibilities from the study, one that they're definitely
better, one that they're the same and one that they were worse," Kantor said.

Although survival rates were about the same with Xyotax, "what made this trial attractive ... is the ease of administration and better safety profile," than
the standard therapy.

Cell Therapeutics is going to meet with the FDA to amend the next study's
primary endpoint to "non-inferiority," instead of significantly improved
survival rates.

That alone should be enough to win approval, the analyst said, pointing to
Eli Lilly & Co.'s (LLY) Alimta product, which last year gained approval as a
second-line non-small lung cancer product, although the company wasn't able to
prove the drug gave patients longer survival rates than those on a competing
drug, Taxotere, which is made by Aventis SA (AVE).

Kantor doesn't own shares, but his firm has investment-banking ties to Cell
Therapeutics.

As of 2004, more than 1 million new lung cancer cases are diagnosed each year
worldwide and nearly 900,000 people die, according to the FDA. It's the leading
cause of cancer deaths in men and the third leading cause of cancer deaths in
women, the FDA said.

[loseit]

Antwort auf Beitrag Nr.: 22.515.875 von loseit am 11.07.06 11:25:28

Hier für alle Neueinsteiger eine recht neutrale Darstellung:

______________________________________________________

Cell Therapeutics' chemo drug gamble
Biotech testing drug to increase cancer survival with chemo and reduce hair loss, nausea
By Aaron Smith, CNNMoney.com staff writer
July 7 2006: 2:56 PM EDT

NEW YORK (CNNMoney.com) -- Cell Therapeutics, a small biotech, is betting its future on an experimental drug that could enhance the effects of chemotherapy while reducing its agonizing symptoms.

On the one hand, it may be a good bet. Xyotax, in clinical trials, reduced hair loss, nausea and vomiting from chemotherapy for lung cancer patients, and in some cases increased the patients' chances for survival. The drug would work by focusing chemotherapy's effects on tumors like a "smart bomb," while reducing the "shotgun" effect of chemo on other parts of the body, said Cell Therapeutics (down $0.02 to $1.40, Charts) CEO James Bianco.
biotech_fund.03.jpg

But it's not a sure bet. The drug failed in a recent late-stage trial to increase survivability when combined to the Bristol-Myers Squibb (up $0.12 to $25.51, Charts) chemotherapy Taxol.

But Bianco said Xyotax seemed to work better on women than men, since estrogen appears to be the catalyst that makes the drug more effective. In fact, Xyotax would have succeeded in the trial if it had been tested on women alone, said Bianco.

So, the Seattle-based biotech is conducting another late-stage study focused exclusively on women, and Bianco hopes to file a Xyotax application with the Food and Drug Administration by mid-2007. If the test is successful and the drug wins FDA approval, the drug might also be used by men taking estrogen.

But if Xyotax tests are not successful, then Cell Therapeutics could suffer yet another hit on its beleaguered stock price, which has plunged 78 percent over the last two years.

Hamed Khorsand, analyst for BWS Financial, has projected peak annual sales of $400 million to $500 million for Xyotax, assuming it succeeds in the current study.

But investing in biotechs is risky and Cell Therapeutics is no exception. Investors in this company would be betting on the success of the Xyotax trials, and the late-stage study for another drug, Pixantrone, for the treatment of non-Hodgkin's lymphoma.

"Investors don't appear to be placing a lot of value on the prospects for Xyotax, or for that matter the rest of the pipeline, based on the stock price," said Paul Latta, analyst for McAdams, Wright, Ragen. "There's probably some wisdom for that, given the record on biotech."

Latta said investors shouldn't overlook Cell Therapeutics, because the market for lung cancer treatment is large and potentially lucrative. However, failing prior trials is a not an inspiring sign, said the analyst.

"The record for do-over trials isn't particularly compelling," said Latta.

As an example, the biotech Vasogen (up $0.01 to $0.46, Charts) faced a similar situation in June, when it announced late-stage study results for Celacade, an experimental treatment for chronic heart failure. A prior Celacade study had failed back in August and the stock price lost two-third of its value. When the company announced another failed trial with Celacade on June 26, the price plunged three-quarters.

Even if Cell Therapeutics' current trials for Xyotax prove to be successful, Khorsand of BWS Financial said he would like to see the biotech license the drug to Cephalon (up $0.57 to $63.68, Charts), as it did last year with its leukemia treatment Trisenox.

"We would rather see them collaborate with someone else," said Khorsand. "Just to see them collaborate with a larger firm would make us more comfortable because that would relieve CTI of the financial burden."

The analysts interviewed for this story do not own shares of Cell Therapeutics stock and their firms do not do business with the biotech.

[DMKE]

Antwort auf Beitrag Nr.: 22.517.127 von loseit am 11.07.06 12:31:04

gehts hier jemals wieder aufwärts ... ?

[loseit]

Antwort auf Beitrag Nr.: 22.584.029 von DMKE am 14.07.06 09:29:54

Das hängt von Xyotax ab, und das dauert noch.

Ich würde im Zuge der allgemeinen Biotech-Depression erstmal mit weiteren Rückgängen rechnen.

Gruss Loseit

[Eppelein]

Ist das management wirklich so übel wie hier behauptet wird?

"Like we said, the only stakeholders being enriched at Cell Therapeutics are Bianco & Company. They remind us of deer ticks, who will just keep sucking the life blood until they become so engorged, they just fall off their victims—still and all, plump and satiated."

http://10qdetective.blogspot.com/2006/07/cell-therapeutics-c…

[timecop64]

23.08.2006 14:47
Cell Therapeutics - Aktie steigt nach positiven Tests
Die Aktien des Biotechnologieunternehmens Cell Therapeutics (Nachrichten) profitieren im vorbörslichen Handel von der Meldung über positive Phase I-Versuche zum Chemotherapeutikum Xyotax in Kombination mit einer Strahlentherapie zur Behandlung von Speiseröhren-und Magenkrebs.

Wie das Unternehmen am Mittwoch weiter mitteilte, haben 91% der getesteten Tumor-Patienten auf die Anwendung angesprochen.

Cell Therapeutics legen vorbörslich um 13% auf 1,47 Dollar zu

[timecop64]

Antwort auf Beitrag Nr.: 23.578.487 von timecop64 am 23.08.06 15:18:35

Nachtrag:

Quelle: Börse Go

[mfierke]

[Eppelein]

Geil!

[Macrocosmonaut [Blogger]]

Antwort auf Beitrag Nr.: 23.425.664 von Eppelein am 13.08.06 02:22:25

Da haben sie ihre Antwort vom Markt heute auf ihre Frage.

Seien Sie vorsichtig bei solchen Nachrichten, sie wissen nie welche Motivation des Verfasser seitens Dritter dahinter steckt.
In einem solchen Fall richten sie sich lieber nach dem Chart.

Ich denke niemand wird bezweifeln, dass es heute bei CTIC einen schönen Impulsswitch gegeben hat.

Ob das gap geschlossen wird wird sich in den nächsten Wochen zeigen.

Gruss.

macro.

[timecop64]

Antwort auf Beitrag Nr.: 23.586.548 von Macrocosmonaut am 24.08.06 00:25:08

Leute - der Anstieg geht weiter.

Bid 1,36.
Ask aktuell bei 1,43 Euronen.

[againstfotsch]

Hallo,
weiß jemand von euch wann die FDA-Entscheidung für Xyotax fällt?
Was meint ihr - hop oder top?
Gruß
af

[loseit]

Antwort auf Beitrag Nr.: 23.592.873 von againstfotsch am 24.08.06 13:05:23

Die Studie war Phase I.
Aktuell steht die Zulassung in Verbindung mit Lungenkrebs an - hier allerdings zeigten sich Effekte nur bei Frauen mit hohem Östrogenpegel - d.h. vor der Menopause.

Die Frage ist hier speziell nicht, ob die Zulassung kommt, sondern auch wenn sie kommt, wie gross der Markt eigentlich ist.

[Eppelein]

Wenn die Zulassung nicht kommt ist egal wie gross der Markt ist.

[Eppelein]

Cell schmeisst manager raus,was ist davon zu halten?

http://phx.corporate-ir.net/phoenix.zhtml?c=92775&p=irol-new…

[loseit]

Antwort auf Beitrag Nr.: 23.732.291 von Eppelein am 02.09.06 13:31:05

has resigned for personal reasons - kann vieles heissen.
Für mich keine Kursrelevanz.

[kiefernberg]

Hallo, wieviel cash hat Cell Therap.? und wie lange reicht das bei derzeitiger Cash-burn-rate??

danke uwe

[loseit]

Antwort auf Beitrag Nr.: 24.680.851 von kiefernberg am 17.10.06 15:47:22

Gerade Kapitalerhöhung durchgeführt - daher auch der Absturz von > 2 $ auf 1,60.

Cash-burn ist ca. 25 Mio. je Quartal.
Kapitalerhöhung um ca. 40 Mio.
Reicht also nicht allzu lange.
Kannst Du im yahoo-Board unter NEWS lesen.

Wichtiger sind die Aussichten von Xyotax.

[kiefernberg]

danke

Uwe

[wolfgangh02]

hoffe hier passiert mal irgendwann etwas. weiß vielleicht jemand näheres???

[pascal12]

irgendetwas ist doch im Busch. Alle Börsenplätze in DE steigen gewaltig auch schon die letzten Tage. und heute wurde an jeder Börse in DE um ca. 11.58Uhr zum höheren Preis gekauft.
Auf der Homepage www.cticseattle.com sind aber keine News!?!?!

Die Arbeiten an Xyontax waren doch ausgesetzt worden oder wie war die News vor 2,3 Wochen aufzufassen?

[wolfgangh02]

Antwort auf Beitrag Nr.: 25.657.853 von pascal12 am 24.11.06 13:12:19

vielleicht stehen ein paar news an und das sind jetzt die insiderkäufe. zeit wäre es ja mal...

[pascal12]

Pfizer Inc Vice President of Corporate Policy and Strategic Management, Fred Telling, to Join Board of Directors of Cell Therapeutics, Inc. (CTI)
SEATTLE, Nov. 29 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced that Frederick W. Telling, Ph.D., has agreed to join its board of directors. Dr. Telling is currently the Vice President of Corporate Policy and Strategic Management for Pfizer Inc. His responsibilities include the management of Pfizer's worldwide policy function and external representation of the company's interests to strengthen Pfizer's ability to anticipate and influence regulatory and competitive trends in the global marketplace. Pfizer is the world's largest research-based, global healthcare company.

"We are pleased to welcome Dr. Telling with his leadership and background in pharmaceutical development, regulatory policy, strategic planning and mergers and acquisitions," said Phillip M. Nudelman, Chairman of the Board of CTI. "His experience makes him an ideal addition to CTI's board as we move forward to get XYOTAX(TM) and pixantrone to patients who will benefit the most."

"Dr. Telling's considerable pharmaceutical company experience and extensive industry background will be invaluable to CTI as we grow our commercial operations," said James A. Bianco, M.D., President and CEO of CTI. "We are honored to have him on board."

Dr. Telling added, "I am delighted to join Cell Therapeutics' Board and support its mission to bring novel medicines to cancer patients. The increasingly complex and time-consuming developmental and regulatory challenges facing all research-based innovative firms are particularly daunting for smaller biotech firms, and I look forward to adding my experience to CTI's dedicated leadership going forward."

Since joining Pfizer in 1977, Telling worked with both their pharmaceutical and diagnostic products divisions, becoming the Director of Planning in 1981. In 1987 his responsibilities were expanded and he was promoted to Vice President, Planning, U.S. Pharmaceuticals. Telling was named Pfizer's Vice President-Corporate Strategic Planning and Policy in 1994 and elected a corporate officer and Vice President of the company. In 2001, Telling assumed his current responsibilities as Vice President-Corporate Policy and Strategic Management.

Telling is a member of the Board of the Biotechnology Industry Organization (BIO), the California Health Care Institute, the New England Healthcare Institute and the Committee for Economic Development (Vice Chairman). He is actively involved in a number of charitable organizations, including the Boards of the March of Dimes National Foundation, the United Hospital Fund, ORBIS, the Smithsonian National Air and Space Museum and the Experimental Aviation Association (EAA). He is also Vice Chairman for the American Foundation for Pharmaceutical Education and an invited faculty lecturer at the Harvard University School of Public Health and Cornell University. He is involved in the work of the Council on Competitiveness, the Business Roundtable, the National Association of Manufacturers, and the Institute of Medicine, where he was a contributing author to the IOM's series on Technology Innovation in Medicine.

Telling received his BA from Hamilton College and his Master's of Industrial and Labor Relations and Ph.D. in Economics and Public Policy from Cornell University.

In addition to Telling, CTI's Board of Directors includes Phillip M. Nudelman, Ph.D., Chairman of the Board, President and Chief Executive of The Hope Heart Institute and former President and CEO of Group Health Cooperative; Vartan Gregorian, Ph.D., President of Carnegie Corporation of New York; Mary O. Mundinger, D.P.H., Dean and Professor, School of Nursing and Associate Dean, Faculty of Medicine, Columbia University; John H. Bauer, former EVP of Finance for Nintendo of America, Inc.; James A. Bianco, M.D., President and CEO of CTI, and Jack W. Singer, M.D., Chief Medical Officer of CTI.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.

[wolfgangh02]

na hoffentlich wird dr. telling den großen erwartungen ihm gegenüber gerecht

[pascal12]

Die Highlights klingen doch ganz gut!


Cell Therapeutics, Inc. (CTI) Provides Update at Its First Ever Annual Shareholder Meeting in Italy
MILAN, Italy, Dec. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) provided a progress report on its development programs and business objectives at its annual shareholder meeting, held in Milan on November 30, 2006.

"While breakthrough advances are being made with targeted therapies, these often come at a high price. We believe that chemotherapy will continue to be a mainstay in the treatment of cancer and CTI's pipeline is focused on reducing side effects and their related health care costs while improving efficacy of the four most widely used classes of chemotherapeutic agents. Our strategy for developing safer, more cost effective treatments for cancer is consistent with increased concerns over rising healthcare costs," stated James A. Bianco, M.D., President and CEO of CTI. "This year CTI has become a 'new' company: focused on advancing our lead products, XYOTAX(TM) and pixantrone, assuring their commercial success through our partnership with Novartis, strengthening our balance sheet, and increasing our visibility among our key audiences."

Highlights


Announced an exclusive worldwide licensing agreement with Novartis for up to $405 million for XYOTAX and pixantrone, including a $15 million equity investment in CTI
Strengthened balance sheet by raising $85 million in gross proceeds, establishing a euro 60 million equity facility with Societe Generale, and converting, exchanging, or repurchasing $170 million of existing debt since November 2005
Provided updates on the XYOTAX development program
200 patients have been enrolled on its phase III lung cancer clinical trial in women (PIONEER)
Plans to submit a new phase III protocol (PGT306) for lung cancer that focuses on women with normal estrogen levels
Working toward submission of marketing application (MAA) for XYOTAX in Europe in 2007


Provided updates on the pixantrone development program
Presentations of clinical data expected at upcoming American Society of Hematology meeting (ASH)
Plans to conduct interim analysis on phase III clinical trial in non- Hodgkin's lymphoma (EXTEND) in 2007
Updated progress on genetic polymer technology for producing potentially lower cost "biosimilars"

CTI Adjourns Annual Shareholder Meeting

CTI held the rescheduled annual shareholder meeting in Milan in an effort to increase Italian shareholder participation. While CTI had unprecedented participation at the meeting from Italian shareholders, it adjourned the meeting because a quorum of the common shares was not represented. Under Washington state law and the Company's bylaws, a quorum consisting of a majority of the shares entitled to vote at the meeting must be represented in person or by proxy in order to transact business at the meeting.

In the absence of a quorum, no action can be taken on the proposals presented in the proxy statement. Therefore, the proposals were tabled and the annual meeting of shareholders was adjourned to give additional time for shareholders to return their proxies. Pursuant to Washington state law, valid proxies submitted by Company shareholders in connection with the meeting will continue to be valid for 120 days, and Dr. Bianco encouraged Italian shareholders to continue to vote their shares as soon as possible by mail, fax, or on the web at proxyvote.com. CTI may explore legal and other options to address the quorum requirements.

Additional Information

The Company's definitive proxy statement with respect to the Annual Meeting of Shareholders scheduled to be held November 30, 2006 was mailed to shareholders on or about October 26, 2006 and was filed with the U.S. Securities and Exchange Commission at that time. SHAREHOLDERS OF CELL THERAPEUTICS, INC. ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT AND ALL ADDITIONAL MATERIALS THAT THE COMPANY FILES WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION RELATING TO THE MEETING. The proxy statement is available free of charge at www.sec.gov. In addition, investors and security holders may obtain free copies of the definitive proxy statement and other documents filed with the SEC on our web site: www.cticseattle.com or by contacting CTI Investor Relations at the address and telephone number below.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include the risk that CTI will be unable to reschedule the annual meeting or unable to get a quorum at the rescheduled meeting of shareholders and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K/A, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


SOURCE Cell Therapeutics, Inc. 12/01/2006


CONTACT: Dan Eramian, [phone], or cell, [phone], or
Susan Callahan, [phone], or fax, [phone], or
[e-mail], or investors, Leah Grant, [phone], or fax,
[phone], or [e-mail], all of Cell Therapeutics, Inc.
Web site: http://www.cticseattle.com
(CTIC)


0121 12/01/2006 17:30 EST http://www.prnewswire.com

[pascal12]

ask bei 1,95$ Wahnsinn!!!!!!!!!

[wolfgangh02]

ich denke wenn hier alles gut geht, sind locker 3,50 drin!

[pascal12]

Antwort auf Beitrag Nr.: 25.972.467 von wolfgangh02 am 06.12.06 15:39:25

wenn die Zulassung kommt gibts keine Grenzen.
standen im Biotechboom 2001 ja schin bei 90€.
Wenn Die Zulassung nicht kommt wird dicht gemacht.
Experten hatte die Entscheidung ja bereits für diesen Herbst vorgesehen, kam aber nix...?!?

[wolfgangh02]

Antwort auf Beitrag Nr.: 25.973.205 von pascal12 am 06.12.06 16:03:35

Wenn Die Zulassung nicht kommt wird dicht gemacht

das sehe ich ebenso. aber mal keine schwarzmalerei. bin ja inzwischen schon fast 1 jahr guter dinge.
negatives war ja bis jetzt auch kaum zu hören.

[pascal12]

wie ist der aktuelle Stand von Xyontax? Da war doch vor ca. 3,4 Wochen diese Meldung über Aussetzung oder so ähnlich der Arbeit auf Grund einer Mitteilung der FDA?

[wolfgangh02]

Antwort auf Beitrag Nr.: 25.975.157 von pascal12 am 06.12.06 17:10:18

SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, (Nachrichten) Inc. (CTI) (Nasdaq: CTIC; MTAX) reported today that enrollment on its PIONEER lung cancer clinical trial has been temporarily suspended while the Company awaits follow up data of recently enrolled patients. After consultation with the Company and the study's steering committee, the Data Safety Monitoring Board (DSMB) recommended and CTI agreed to suspend enrollment on the trial to allow maturity of the data and assessment of differences in early cycle deaths observed between arms of the study. While most of the deaths were attributed to disease progression, more complete data is required to analyze this difference. Also according to the recommendation of the DSMB, all patients who are currently on the trial will continue to be treated per the protocol.

In addition, as a planned follow up to its May meeting with and following recommendations from the U.S. Food and Drug Administration (FDA), the Company reviewed the demographic and estrogen data of the patients on the PIONEER study and plans to amend the current study while enrollment is suspended. The study will be amended to focus on the primary efficacy endpoint of survival in women with normal estrogen levels; the subset of patients that demonstrated the greatest survival benefit in the STELLAR trials.

"Following our meeting with the FDA, we decided to use the initial enrollment in this study to determine whether the proportion of patients who have normal estrogen levels is equivalent to what was expected based on our experience in the STELLAR trials," said James A. Bianco, M.D., President and CEO of CTI. "Given that only approximately one-half of patients sampled have normal estrogen levels in the PIONEER trial compared to approximately two- thirds of patients for which estrogen data was available in our prior STELLAR trials, we decided it would be prudent to amend the protocol to focus the primary endpoint analysis on the subgroup of patients in which we saw the greatest survival difference in our STELLAR trials -- patients with normal estrogen levels."

The PIONEER study was initiated in December 2005 using pre-menopausal age to stratify patients. Based on feedback from the FDA, CTI will utilize the Agency's recommendation to amend the protocol to use estrogen level as a stratification factor and as the primary efficacy endpoint of the study. The Company expects to submit an amendment to the FDA under a Special Protocol Assessment request as soon as practicable. The Company anticipates the change to the protocol will push the interim analysis of the PIONEER trial back by at least six months.

About the PIONEER Clinical Trial

The PIONEER clinical trial is targeting approximately 170 sites in North and South America, Europe, and Asia. The trial was originally designed to enroll approximately 600 PS2 chemotherapy-naive women with advanced stage NSCLC. Each study arm will be randomized to receive either XYOTAX (paclitaxel poliglumex) (at a dose of 175mg/m2 paclitaxel equivalents) or paclitaxel (at a dose of 175mg/m2) once every three weeks. The primary endpoint is superior overall survival with several secondary endpoints including disease control, response rate in patients with measurable disease, time to disease progression, and disease-related symptoms. For more information on the PIONEER trial, call 1-800-715-0944.

About XYOTAX

XYOTAX(TM) (paclitaxel poliglumex) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com/.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of XYOTAX include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with XYOTAX in particular including, without limitation, the potential failure of XYOTAX to prove safe and effective for treatment of non-small cell lung cancer, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling XYOTAX, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward- looking statements whether as a result of new information, future events, or otherwise.

[pascal12]

da drückt aber einer gewaltig den Kurs. Pari zu USA wäre 1,42€

[pascal12]

good news!

Cell Therapeutics, Inc. (CTI) Closes PGT305 (PIONEER) Lung Cancer Clinical Trial; New PGT306 Protocol to Be Submitted to FDA by Year End
SEATTLE, Dec 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC) today announced that the Company and the Data Safety Monitoring Board (DSMB) agreed to close the PGT305 PIONEER lung cancer clinical trial and take patients off both treatment arms. CTI's decision was due, in part, to the utility of the current trial given its plans to submit a new protocol to the United States Food and Drug Administration (FDA) and in light of the aberrantly low rate of deaths in the control group. CTI plans to submit a new protocol by the end of the year, under a Special Protocol Assessment, to the (FDA). The new protocol, PGT306, will focus exclusively on women with normal estrogen levels, the subset where XYOTAX has demonstrated the greatest survival advantage in the STELLAR trials.

"While the patients in the PIONEER PGT305 study will not count toward our final pivotal trial results, the data from this trial will be instrumental in helping us understand the unique properties of this biologically enhanced chemotherapeutic and its potential as a gender specific therapy for women with lung cancer and other tumors where estrogen can influence the uptake and metabolism of XYOTAX," said CTI President and CEO, James A. Bianco, M.D.

About XYOTAX

XYOTAX(TM) (paclitaxel poliglumex) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com .

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of XYOTAX include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with XYOTAX in particular including, without limitation, the potential failure of XYOTAX to prove safe and effective for treatment of non-small cell lung cancer, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling XYOTAX, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward- looking statements whether as a result of new information, future events, or otherwise.

SOURCE Cell Therapeutics, Inc.


media, Dan Eramian, [phone], or mobile, [phone], or Susan Callahan,
[phone], or fax, [phone], or [e-mail], or investors, Leah
Grant, [phone], or fax, [phone], or [e-mail], all of
Cell Therapeutics, Inc.

http://www.cticseattle.com

[pascal12]

äh doch nicht so gut, gemäß seattle Times wirft es CTIC um 6 Monate zurück. Die Zukunft von xyontax ist doch sehr ungewiss Wundert mich dass es keinen Verkaufsdruck gibt?!?


Key trial of Cell Therapeutics lung cancer drug ends
By Luke Timmerman

Seattle Times business reporter

Cell Therapeutics said late Thursday it has shut down its most important clinical trial because patients who took its cancer drug were dying more quickly than those receiving a standard chemotherapy drug.

The Seattle biotech company, which suspended the trial a month ago, will submit a newly designed study to the Food and Drug Administration by year's end. The company said data from the 200 patients who were treated so far will not be used if it eventually seeks FDA approval for the drug, called Xyotax.

The trial, called Pioneer, had the unusual feature of being limited exclusively to women with lung cancer.

Cell Therapeutics originally planned to enroll 600 at 170 medical centers. Patients in the study had advanced lung cancer and a life expectancy of 8 to 10 weeks.

Dan Eramian, a company spokesman, said patients taking the company's drug lived about as long as expected based on earlier studies, but patients in the control group lived unusually long.

He said the company has ruled out the possibility that contamination or toxicity from its drug might be killing patients prematurely, and the difference remains unexplained.

The drug already has failed three major lung cancer trials that enrolled both men and women, but the company said it isn't giving up on Xyotax.

Eramian said the company plans to test the drug in 300 women, but only in women with normal estrogen levels.

The company said that the new design is based on experience in earlier studies. Xyotax, a polymer molecule that modifies chemotherapy to make it more tolerable, is believed to react positively with estrogen.

In the next study, the company hopes it will show its drug provides a survival advantage, so it can win approval for the market.




"You need to go to the FDA with something you can win with," Eramian said.

The trial shutdown will put the company at least six months behind its schedule for completing the trial, Eramian said.

That will cost the company precious time and money. In its last quarterly report, Cell Therapeutics said it had $68 million in cash at the end of September, and it subsequently received a $15 million payment from its partner Novartis.

Cell Therapeutics, which has never turned a profit in its 15-year history, is spending money at a rate of close to $10 million a month.

Xyotax isn't its only drug. Cell Therapeutics also expects to receive results in the first half of 2007 from a study of another drug, Pixantrone, for non-Hodgkin's lymphoma.

Cell Therapeutics stock closed down 7 cents Thursday to close at $1.82 a share.


Luke Timmerman: 206-515-5644 or [e-mail]

[wolfgangh02]

ich vermute, dass sich hier eh alle auf long eingestellt haben. und bei den verlusten die hier viele hatten lohnt sich ein verkauf jetzt vermutlich auch nicht mehr. da bleibt nur noch die hoffnung. warum schreibst du eigentlich immer xyontax?

[pascal12]

ich verkaufe sie jetzt. CTIC war immer meine Lieblingsaktie, aber die Möglichkeiten auf Zulassung eines Medikaments verschlechtern sich ja immer mehr. Habe mit einigen Stücken Verluste bereits realisiert aber mit meinem jetzigen machen ich 35% Gewinn. Ist okay.
Wünsche Euch viel Erfolg, dass es doch noch mit dem Bumm klappt. Vielleicht komme ich ja wieder

[pascal12]

der letzte Pfeil im Köcher...
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
CPOP Combination Therapy With Pixantrone Results in 73 Percent Overall Response Including 47 Percent Complete Response

ORLANDO, Fla., Dec. 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC) today announced results from a phase II study of CPOP combination therapy with pixantrone for patients with relapsed aggressive NHL. The results, presented at the 48th Annual Meeting of the American Society of Hematology (ASH), showed a 73 percent overall response rate (ORR), including 47 percent experiencing complete disappearance of their tumors (complete response, CR). These patients had received prior first-line regimens containing anthracyclines and due to dose limitations for potential cardiotoxicity were not eligible to be retreated with standard anthracyclines.

"These data suggest that in the relapsed setting where patients have already received prior regimens containing anthracyclines, the CPOP combination has substantial activity with a notable complete remission rate and a low rate of serious cardiac events," said Andreas Engert, M.D., Professor for Internal Medicine, Hematology and Oncology, University Hospital of Cologne and principal investigator on the study.

Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive NHL (Publication #529)

In an oral session, Peter Borchmann, M.D., Ph.D., Senior Consultant, Hematology and Oncology, University Hospital of Cologne and investigator on the study, presented results from a phase II clinical trial of pixantrone combination therapy, known as CPOP, in patients with relapsed aggressive NHL -- all of whom had received prior regimens containing anthracyclines. In the CPOP regimen, pixantrone replaces doxorubicin in the standard CHOP regimen.

Of the 30 patients evaluable for response, 73 percent (22 patients) achieved an objective response, including 47 percent (14 patients) experiencing a complete response (CR) and 26 percent (8 patients) achieving a partial response (PR). The median duration response was 10.2 months (95 percent confidence interval: range 6.7 to 23 months). The predominant side effects (grade 3/4) were hematologic including neutropenia (97 percent), leukopenia (90 percent), lymphopenia (53 percent), anemia (30 percent), thrombocytopenia (20 percent), and febrile neutropenia (20 percent). Preliminary results from this study were announced in March 2006.

About the CPOP Study

This trial examined the safety and potential efficacy of pixantrone when substituted for doxorubicin in the CHOP regimen among patients who failed prior doxorubicin-containing CHOP therapy for aggressive NHL. Patients received a median of six cycles of therapy (range one to 6). Dosing for the CPOP regimen was pixantrone at 150 mg/m(2) on day l, cyclophosphamide at 750 mg/m(2) on day l, vincristine at 1.4 mg/m(2) on day l, and prednisone at 100 mg on days 1 through 5, each three-week cycle.

About the CHOP Regimen

The CHOP chemotherapy regimen (a combination of cyclophosphamide, vincristine, prednisone and doxorubicin) in combination with rituximab for CD20+ patients is the standard-of-care treatment for newly diagnosed (first-line) aggressive NHL. Response rates following CHOP in first-line aggressive NHL can reach 70 percent and the regimen is potentially curative in up to 40 percent of patients. The prognosis is poor for patients who have a recurrence of the disease (relapsed patients). Despite its impressive anti- tumor activity, CHOP often cannot be used to retreat the 60 to 65 percent of patients who will relapse following CHOP, due to the cumulative cardiotoxicity associated with one of its constituent agents, doxorubicin; a chemotherapy agent which belongs to the anthracycline family. The maximum lifetime recommended dose of doxorubicin is 450 mg/m(2). During first-line treatment with CHOP most patients receive between 300 and 400 mg/m(2) of doxorubicin.

"The data presented at ASH suggest that in the relapsed setting for both aggressive and indolent NHL, the use of pixantrone offers patients a high probability of achieving a complete response with an acceptable safety profile, even in pretreated patients," said Scott C. Stromatt, M.D., Executive Vice President of Clinical Development and Regulatory Affairs at CTI. "We look forward to further results from our ongoing pixantrone trials."

CTI is also studying pixantrone in two ongoing trials -- a phase III single agent study for relapsed aggressive NHL known as the EXTEND trial and a phase II combination study (CPOP-R versus CHOP-R) for first-line treatment of aggressive NHL, known as the RAPID trial. Interim results for the EXTEND trial are scheduled late in the first half of 2007.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplified administration compared to the currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com .

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone] to prove safe and effective for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

[Pitti72]

7:00AM Cell Therapeutics files for Special Protocol Assessment With FDA for Xyotax lung cancer trial in women (CTIC) 1.72 : Co announces that it has filed for a Special Protocol Assessment with the FDA for the design of its phase III trial of Xyotax for women with advanced lung cancer. The trial, PGT306, will focus exclusively on women with normal estrogen levels, the subset where Xyotax demonstrated the greatest survival advantage in the Stellar trials. The trial is expected to enroll 300 poor performance status women who have advanced stage non-small cell lung cancer and have not received prior chemotherapy.

[pascal12]

Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) With FDA for XYOTAX Lung Cancer Trial in Women
CEO Reviews 2006 Accomplishments and Milestone Targets for 2007
SEATTLE, Jan. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced it has filed for a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for the design of its phase III trial of XYOTAX for women with advanced lung cancer. The trial, PGT306, will focus exclusively on women with normal estrogen levels, the subset where XYOTAX demonstrated the greatest survival advantage in the STELLAR trials. The trial is expected to enroll 300 poor performance status (PS2) women who have advanced stage non-small cell lung cancer (NSCLC) and have not received prior chemotherapy. Only women with normal estrogen levels either as a result of pre-menopausal age or hormone replacement therapy will be randomized in the follow-on study to the PIONEER trial.

"Through our clinical studies in 2006, we have gained important insights into the best lung cancer patient population to target our XYOTAX pivotal trial effort in order to minimize end-of-trial surprises while maximizing the probability of success. We look forward to feedback and guidance from the FDA on our phase III trial," said James A. Bianco, M.D., President and CEO of CTI. "Lung cancer continues to be the number one cancer killer of women. Better treatments are needed to combat this disease that will kill more than 70,000 women this year."

In addition, Bianco reviewed CTI accomplishments for 2006 and identified important Company milestones for 2007:

-- "In 2006 the Company made significant progress in positioning XYOTAX,
if approved, for successful commercialization," said Bianco. "A major
development was the establishment of a potential $285 million
commercial and development partnership for XYOTAX with Novartis,
providing the global expertise and resources of one of the leading
multi-national oncology companies."
-- In addition the Company received positive advice and agreement from the
EMEA's Scientific Advice Working Party (SAWP) to switch from the
superiority endpoint in the STELLAR 4 trial to a non-inferiority
endpoint for XYOTAX. CTI plans to file a marketing authorization
application (MAA) in Europe in 2007 for XYOTAX as a single agent for
first-line treatment of non-small cell lung cancer (NSCLC) in men and
women PS2 patients. "Given the recent article in the Journal of the
National Cancer Institute showing the economic toll of the hours lost
to cancer care, we believe the SAWP agreement recognizes this important
and often overlooked reality," said Bianco.

"For our other phase III product, pixantrone, we recently presented positive clinical data at the American Society of Hematology (ASH) meeting showing high overall responses from two pixantrone studies. In addition, based on interim data from the first 40 patients on the EXTEND trial, a randomized phase III study of pixantrone for patients with aggressive non-Hodgkin's lymphoma (NHL), the Data Monitoring Committee recommended the study continue," Bianco added.

"2006 was a rebuilding year for the Company, establishing an important partnership while advancing our two lead drug candidates toward market. With two key regulatory events for XYOTAX and pixantrone, 2007 promises to be a pivotal transition for the Company and its products."

Key Target Milestones for 2007
-- Reach Special Protocol Assessment agreement with FDA on PGT306 pivotal
trial for XYOTAX in women with lung cancer and initiate enrollment at
approximately 200 centers worldwide
-- Reach Special Protocol Assessment agreement with FDA on PIX303 pivotal
trial for pixantrone in first-line and second-line indolent NHL and
initiate enrollment at more than 100 centers worldwide
-- File a marketing authorization application (MAA) in Europe in 2007 for
XYOTAX as a single agent for first-line treatment of non-small cell
lung cancer (NSCLC) in PS2 patients
-- Conduct interim analysis on phase III pixantrone clinical trial in
relapsed aggressive NHL (EXTEND trial) and if compelling, meet with FDA
to discuss potential registration strategy
-- Maintain burn rate at 2006 level, continue to strengthen and
de-leverage balance sheet

About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com .

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of XYOTAX and pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with XYOTAX and pixantrone in particular including, without limitation, the potential failure of XYOTAX and pixantrone to prove safe and effective for treatment of non -small cell lung cancer and non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling XYOTAX and pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward- looking statements whether as a result of new information, future events, or otherwise.

SOURCE Cell Therapeutics, Inc.
-0- 01/10/2007
/CONTACT: Dan Eramian, [phone], or cell, [phone], or
Susan Callahan, [phone], or [e-mail], or investors, Leah
Grant, [phone], or [e-mail], all of Cell Therapeutics,
Inc./
/Web site: http://www.cticseattle.com/
(CTIC)

CO: Cell Therapeutics, Inc.
ST: Washington
IN: BIO MTC HEA
SU: WOM FDA

JB
-- SFW035 --
6241 01/10/2007 07:00 EST http://www.prnewswire.com

[wolfgangh02]

Antwort auf Beitrag Nr.: 26.813.812 von pascal12 am 10.01.07 16:46:45

Bist du wieder dabei??

[pascal12]

Antwort auf Beitrag Nr.: 26.930.531 von wolfgangh02 am 15.01.07 10:29:06

nein, werde Cell aber immer auf meiner Watchlist haben...

[wolfgangh02]

ich glaube nicht, dass es noch einmal so weit runter geht wie im oct. und wenn doch noch viele tiefer.

[GuHu1]

in den letzten tagen hat sich der wert wieder ein bischen berappelt.
liegt das an der korrigierten bilanz von 2005?

da hat man sich zu eigenen ungunsten um ein zwei millionen verrechnet.

[wolfgangh02]

Antwort auf Beitrag Nr.: 28.300.318 von GuHu1 am 14.03.07 22:25:55

ich weiß von nichts. bin long und sehe hier kaum rein. aber wenn du es rausfindest stells doch einfach rein.

[GuHu1]

Bin übrigens auch long

SEATTLE, March 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, (Nachrichten) Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced it has filed for a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for the design of its phase III trial of pixantrone for patients with indolent non- Hodgkin's lymphoma (NHL). The trial, PIX303, will examine the complete remission rates and time to disease progression of the combination regimen of fludarabine, pixantrone and rituximab (FP-R) compared to the combination of fludarabine and rituximab (F-R) in the treatment of patients who have failed up to five prior treatments for relapsed or refractory indolent NHL. The trial is expected to enroll 300 patients.

"The impressive complete remission rates and durable survival data in our phase II combination study for indolent NHL patients provides the rationale for conducting a phase III study and we look forward to feedback and guidance from the FDA on the study design," said James A. Bianco, M.D., President and CEO of CTI. "Pixantrone has shown encouraging activity in both indolent and aggressive NHL especially in the relapsed setting, paving a route for a potential registration across both types of NHL thus potentially doubling the size of the market potential in lymphoma."

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplified administration compared to the currently marketed anthracyclines.

Pixantrone in Indolent NHL

Preliminary results from a phase I/II study of pixantrone combined with fludarabine, dexamethasone, and rituximab for patients with relapsed indolent NHL were presented at the American Society of Hematology (ASH) annual meeting in December, 2006. Among the 27 patients evaluable for response, study results showed the FPD-R regimen with pixantrone produced an 89 percent overall response rate (ORR) by the Cheson criteria, including 70 percent of patients experiencing a complete response/unconfirmed complete response (CR/uCR; 63 percent, CR and seven percent, u/CR). The estimated median duration of response was 25 months and the estimated progression-free survival rate at three years was 50.4 percent. In addition, pixantrone was studied in a randomized clinical trial for indolent NHL patients comparing pixantrone in combination with rituximab to rituximab alone, with time to progression (TTP) as the primary efficacy endpoint. The study of 38 relapsed or refractory patients receiving the combination of rituximab and pixantrone had an 87 percent overall improvement in TTP compared to rituximab alone. The median TTP estimate for the pixantrone/rituximab recipients was 13.2 months compared to 8.1 months for rituximab alone (hazard ratio 0.13, log rank p<0.001). The one- and two-year progression-free survival estimates were 66 percent and 44 percent for the pixantrone/rituximab recipients compared to zero percent for the rituximab recipients for both measurement intervals (p<0.001 and 0.003, respectively).

Pixantrone in Aggressive NHL

Pixantrone has been studied extensively in aggressive NHL patients, including two ongoing studies, a phase III single agent trial, known as EXTEND and a phase II combination study, known as RAPID. The EXTEND trial explores the role of single agent treatment as a salvage regimen in patients with relapsed aggressive NHL who have failed at least two prior treatment regimens.

Patients are randomized to receive either pixantrone or another single-agent drug of physician's choice currently used for the treatment of this patient population. An interim look is planned for the summer of 2007.

The RAPID trial is a first-line phase II study in aggressive NHL patients that will evaluate pixantrone as part of the CPOP-R combination regimen (cyclophosphpamide, pixantrone, vincristine, prednisone and rituximab) compared to the standard treatment regimen, CHOP-R (cyclophosphpamide, doxorubicin, vincristine, prednisone and rituximab). This study will explore the potential cardiac safety benefits of pixantrone in chemotherapy naïve patients when compared directly to doxorubicin.

About NHL

According to the SEER CanQuest Database and the American Cancer Society, in 2005 the prevalence of aggressive NHL in the U.S. was 99,880 with 31,900 newly diagnosed patients. The prevalence of indolent NHL in the U.S. was 282,025 with 24,490 newly diagnosed patients.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com/.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward- looking statements whether as a result of new information, future events, or otherwise.

[wolfgangh02]

Antwort auf Beitrag Nr.: 28.307.566 von GuHu1 am 15.03.07 12:45:14

hier hat man ja auch keine große wahl
ist aber schön, dass es vorwärts geht.

[wolfgangh02]

Cell Therapeutics Gains on Xyotax Fast-Track, Tractor Supply Beats; Verasun Downgraded


NEW YORK (AP) -- Cell Therapeutics Inc. stock jumped in premarket trading Wednesday after the drug maker said the Food and Drug Administration has fast-tracked development of one of its cancer drugs.
The Seattle-based company said Xyotax, described as a "biologically-enhanced" version of chemotherapy drug Taxol, will get a phase III clinical trial for non-small cell lung cancer. The subjects will be women who have not received chemotherapy and have poor prognosis, including metastases or advanced stage IV cancer.

[carpiediem]

Antwort auf Beitrag Nr.: 28.778.018 von wolfgangh02 am 12.04.07 15:57:39

hi wolfgang,

kannst du das Wichtigste in good old germany zusammenfassen?

Wäre nett!! Danke

mfg carpe diem

[wolfgangh02]

abacho.de
nicht der hit, ist für umsonst aber ok.

[RazorLux]

Hallo,

ist Cell vom Handel ausgesetzt?

[carpiediem]

Antwort auf Beitrag Nr.: 28.842.058 von RazorLux am 16.04.07 18:53:33

Das frage ich mich auch?

Hat jemand eine Antwort?

[GuHu1]

ich schaue gerade bei onvista rein und sehe einen kurs von € 4,51!!!!
laut onvista + 291 %.

was ist los, übernahme oder was.
ich wollte das teil schon abstoßen und dann sowas, dzdzdz.

[GuHu1]

Antwort auf Beitrag Nr.: 28.798.407 von wolfgangh02 am 13.04.07 17:48:48

hey wolfgang, wach auf, du warst doch auch long nun veruch mal ein paar infos ranzukriegen.

[GuHu1]

bin ich echt einer der einzigen kleininvestoren der hier ne long position hat ???

[GuHu1]

SEATTLE, April 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced that it has entered into agreements to sell approximately $37.2 million of its 3% Convertible Preferred Stock and warrants in a registered offering to several institutional investors, including existing securities holders. CTI will sell Series B convertible preferred stock and warrants to investors at the negotiated price of $1,000 per share of Series B convertible preferred stock. The Preferred Stock will be convertible into shares of common stock beginning on April 16, 2007, at a conversion price of $1.6825 per share ($6.73 per share following the one-for-four reverse stock split effective on April 15). Purchasers will also receive warrants to purchase common stock in an amount equal to 50% of their total investment amount divided by $1.6825 ($6.73 post-split), which warrants will have an exercise price of $1.62 per share ($6.48 post-split), which is equal to the closing bid price of the Company's common stock as reported on the Nasdaq Global Market on April 10, 2007. The warrants will not be exercisable until six months following the closing.

The offering is expected to close on April 16, 2007, subject to certain closing conditions.

Rodman & Renshaw, LLC acted as the exclusive placement agent for the offering.

A shelf registration statement relating to the preferred stock and warrants to be issued in the offering has been filed with the Securities and Exchange Commission and has become effective. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our Convertible Preferred Stock or warrants. No offer, solicitation, or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. The risks and uncertainties include the risk that the above described transaction will not close as a result of the failure to meet closing conditions, investors may breach or withdraw their commitment, and until closed there is no assurance that it will close or what the total amount may be, and other risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or

[carpiediem]

Antwort auf Beitrag Nr.: 28.845.559 von GuHu1 am 16.04.07 21:49:20

hi Guhu,

als alter Lateiner hab ich mit dem Englisch nicht so!!

Was ist die Kernaussage??

Danke ! Über 4 Euro ....?? kann ja nicht??

carpe

[coheho]

Antwort auf Beitrag Nr.: 28.847.340 von carpiediem am 16.04.07 22:40:16

one-for-four reverse stock split
=> Für vier alte erhälst Du eine neue eingebucht !!

[Pitti72]

Hallo!

Es gab einen Reverse Split.

[wolfgangh02]

feiner deutsch:
Biotech betäuben Entwickler Cell Therapeutics Inc (Nachrichten) sagte am Dienstag seine Aktionäre, die gewählt sind, um die Zahl von autorisierten Anteilen zu 410 Millionen von 210 Millionen zu vergrößern. Die Gesellschaft wird auch die Zahl von autorisierten Anteilen der Stammaktie zu 400 Millionen von 200 Millionen vergrößern. Am 15. April, der der erwartete Tag des Inkrafttretens eines eines für vier Rückstammaktie-Spalts ist, werden autorisierte Anteile der Stammaktie 100 Millionen, mit ungefähr 40 Millionen Anteilen ausgegeben und hervorragend sein. 'Die Zunahme in der Zahl von autorisierten Anteilen der Stammaktie versorgt Zelltherapeutik mit der Flexibilität, um Transaktionen zu übernehmen, um unser zukünftiges Geschäftswachstum, einschließlich potenzieller Produktanschaffungen, Partnerschaften, oder Finanzierung zu unterstützen,' sagte Louis A. Bianco, Hauptfinanzoffizier in einer bereiten Behauptung. Anteile fielen 7 Cent, oder 4.1 Prozent zu 1.63 $ während des Nachmittags, auf der Nasdaq-Aktienbörse handelnd. Das Lager hat zwischen 1.12 $ und 2.53 $ während der letzten 52 Wochen gehandelt.

[wolfgangh02]

WKN: 906780
Verhältnis: 1:4 (reverse stock split)
Splittdatum 16.04.2007

[carpiediem]

Antwort auf Beitrag Nr.: 28.876.612 von wolfgangh02 am 18.04.07 12:25:56

hallo,

danke für die Auskunft. Den Splitt habe ich herausgelesen!

Aber wann wird wieder gehandelt??

[Pitti72]

Antwort auf Beitrag Nr.: 28.882.251 von carpiediem am 18.04.07 17:12:50

Hallo!

In US ist handel.

http://finance.yahoo.com/q?s=CTICD

[carpiediem]

Antwort auf Beitrag Nr.: 28.884.897 von Pitti72 am 18.04.07 19:19:17

o.k. habe ich gefunden!!

Wann wird in Deutschland wieer gehandelt???

mfg carpe

[Pitti72]

Antwort auf Beitrag Nr.: 28.899.169 von carpiediem am 19.04.07 14:36:11

Hallo!

In Deutschland wird auch schon gehandelt.
Tippe oben die ISIN NR.US1509344040 ein.
Von dieser Seite hier können wir uns
verabschieden.

Gruß Pitti

[carpiediem]

Antwort auf Beitrag Nr.: 28.901.074 von Pitti72 am 19.04.07 15:52:53

hi pitti ,

danke für deine schnelle Antwort.
Was meinst du mit oben?
Warum verabschieden?
Warum gibt Wden Kursverlauf nicht an?

carpe

[Pitti72]

Ganz einfach.
Anstatt der WKN.906780 mußt du jetzt
US1509344040 oder cep1 eingeben.

mfg Pitti

[carpiediem]

Antwort auf Beitrag Nr.: 28.901.074 von Pitti72 am 19.04.07 15:52:53

halo pitti,

alles klar. Habe ich gefunden!
Kurs 4,20 Euro. Umsatz 23 Teile - Gewaltig!!!
Wenn ich mal da nicht die Kohle in den Sand gesetzt habe.
Habe in den letzten Wochen des öfteren eine Verkaufsorder gesetzt.
Bin nie bedient worden. das kann ja heiter werden!

Grüße carpe

[Pitti72]

Antwort auf Beitrag Nr.: 28.903.988 von carpiediem am 19.04.07 17:55:37

Hallo carpe!

Geht doch.
Ich bin long,habe noch zeit.
Wird schon werden,da bin ich mir ganz sicher(hoffe ich:rolleyes
Bitte neue News und Komentare auf der neuen Seite(ISIN.US1509344040 oder cep1).

Mfg Pitti